The role of methylation in urological tumours

Archivos Espanoles de Urologia

Volumn 66, Issue 5, 2013, Pages 432-439

  Van Der Heijden, Antoine G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biolog a molecular; Bladder; Cancer; DNA methylation; Kidney; Prostate; Testis; Wilm's tumour

Indexed keywords

ADENOCARCINOMA; ANIMAL; BLADDER TUMOR; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; KIDNEY CARCINOMA; MALE; METABOLISM; NEOPLASM; NEPHROBLASTOMA; PATHOLOGY; PROSTATE TUMOR; REVIEW; TESTIS TUMOR; URINARY TRACT CANCER;

ADENOCARCINOMA; ANIMALS; CARCINOMA, RENAL CELL; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; PROSTATIC NEOPLASMS; TESTICULAR NEOPLASMS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS; WILMS TUMOR;

EID: 84879173072     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4: 143-53.
2. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002 Jun;3(6):415-28.
3. Laird PW, Jaenisch R. DNA methylation and cancer. Hum Mol Genet. 1994;3:1487-95.
4. Bernardino J, Roux C, Almeida A, Vogt N, Gibaud A, Gerbault-Seureau M, et al. DNA hypomethylation in breast cancer: an independent parameter of tumor progression? Cancer Genet Cytogenet. 1997;97(2):83-9.
5. Dunn BK. Hypomethylation: one side of a larger picture. Ann N Y Acad Sci. 2003;983:28-42.
6. Silverman AL, Park JG, Hamilton SR, Gazdar AF, Luk GD, Baylin SB. Abnormal methylation of the calcitonin gene in human colonic neoplasms. Cancer Res. 1989, 1;49(13):3468-73.
7. Makos M, Nelkin BD, Reiter RE, Gnarra JR, Brooks J, Isaacs W, et al. Regional DNA hypermethylation at D17S5 precedes 17p structural changes in progression of renal tumors. Cancer Res. 1993, 15;53(12):2719-22.
8. Bartolomei MS. Epigenetics: role of germ cell imprinting. Adv. Exp. Med. Biol. 2003; 518: 239-245.
9. Barletta JM, Rainier S, Feinberg AP. Reversal of loss of imprinting in tumor cells by 5-aza-2'-deoxycytidine. Cancer Res. 1997, 1;57(1):48-50.
10. Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature. 1993; 362: 749 - 751.
11. Mostofi FK, Sesterhenn IA. World Health Organization International Histological Classification of Tumours: histological typing of testis tumours, 2nd edition. Berlin : Springer-Verlag, 1998.
12. Smiraglia DJ, Szymanska J, Kraggerud SM, Lothe RA, Peltomäki P, Plass C. Distinct epigenetic phenotypes in seminomatous and nonseminomatous testicular germ cell tumors. Oncogene 2002;21: 3909-16.
13. Smith-Sørensen B, Lind GE, Skotheim RI, Fosså SD, Fodstad Ø, Stenwig AE, et al. Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer. Oncogene 2002;21: 8878-84.
14. Koul S, Houldsworth J, Mansukhani MM, Donadio A, McKiernan JM, Reuter VE, et al. Characteristic promoter hypermethylation signatures in male germ cell tumors. Mol Cancer 2002;1: 8.
15. Honorio S, Agathanggelou A, Wernert N, Rothe M, Maher ER, Latif F. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours. Oncogene 2003;22: 461-6.
16. Manton KJ, Douglas ML, Netzel-Arnett S, Fitzpatrick DR, Nicol DL, Boyd AW, et al. Hypermethylation of the 5 CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis. Br J Cancer 2005;92: 760-9.
17. Koul S, McKiernan JM, Narayan G, Houldsworth J, Bacik J, Dobrzynski DL, et al. Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Mol Cancer 2004;3: 16.
18. Lind GE, Skotheim RI, Fraga MF, Abeler VM, Esteller M, Lothe RA. Novel epigenetically deregulated genes in testicular cancer include homeobox genes and SCGB3A1 (HIN-1). J Pathol 2006;210: 441-9.
19. Wermann H, Stoop H, Gillis AJ, Honecker F, van Gurp RJ, Ammerpohl O, et al. Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance. J. Pathol. 2010; 221: 433-42.
20. Gaspar-Maia A, Alajem A, Meshorer E, Ramalho-Santos M. Open chromatin in pluripotency and reprogramming. Nat. Rev. Mol. Cell Biol. 2011; 12: 36-47.
21. Huff V. Wilms tumor genetics. Am J Med Genet. 1998, 2;79(4):260-7.
22. Astuti D, Latif F, Wagner K, Gentle D, Cooper WN, Catchpoole D, et al. Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour. Br J Cancer. 2005, 25;92(8):1574-80.
23. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science. 2007, 2;315(5812):642-5.
24. Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, et al. National Wilms Tumor Study Group. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005, 10;23(29):7312-21.
25. Maschietto M, Piccoli FS, Costa CM, Camargo LP, Neves JI, Grundy PE, et al. Gene expression analysis of blastemal component reveals genes associated with relapse mechanism in Wilms tumour. Eur J Cancer. 2011;47(18):2715-22.
26. Ohshima J, Haruta M, Fujiwara Y, Watanabe N, Arai Y, Ariga T, et al. Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor. Pediatr Blood Cancer. 2012;59(3):499-505.
27. Russo P. Contemporary understanding and management of renal cortical tumors. Urol Clin North Am. 2008;35(4):xiii-xvii.
28. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183(2):131-3.
29. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor-suppres sor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A. 1994, 11;91(21):9700-4.
30. McRonald FE, Morris MR, Gentle D, Winchester L, Baban D, Ragoussis J, et al. Methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer. 2009, 3;8:31.
31. Girgis AH, Iakovlev VV, Beheshti B, Bayani J, Squire JA, Bui A, et al. Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res. 2012, 15;72(20):5273-84.
32. Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, et al. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene. 2010, 8;29(14):2104-17.
33. Seliger B, Handke D, Schabel E, Bukur J, Lichtenfels R, Dammann R. Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma. J Transl Med. 2009, 26;7:90.
34. Kagara I, Enokida H, Kawakami K, Matsuda R, Toki K, Nishimura H, et al. CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma. J Urol. 2008;180(1):343-51.
35. Urakami S, Shiina H, Enokida H, Hirata H, Kawamoto K, Kawakami T, et al. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res. 2006, 1;12(23):6989-97.
36. Dalgin GS, Drever M, Williams T, King T, DeLisi C, Liou LS. Identification of novel epigenetic markers for clear cell renal cell carcinoma. J Urol. 2008;180(3):1126-30.
37. McRonald FE, Morris MR, Gentle D, Winchester L, Baban D, Ragoussis J, et al. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer. 2009, 3;8:31.
38. Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl. 2008;(218):12-20.
39. Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst. 2006, 19;98(14):996-1004.
40. Renard I, Joniau S, van Cleynenbreugel B, Collette C, Naômé C,Vlassenbroeck I, et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol. 2010;58(1):96-104.
41. Chung W, Bondaruk J, Jelinek J, Lotan Y, Liang S, Czerniak B, et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1483-91.
42. Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M, Skotheim RI,et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res. 2010, 1;16(23):5842-51.
43. Costa VL, Henrique R, Danielsen SA, Eknaes M, Patrício P, Morais A, et al. TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics. 2011, 1;6(9):1120-30.
44. Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL, et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res. 2011, 1;17(17):5582-92.
45. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A. 1994, 22;91(24):11733-7
46. Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X, De Marzo AM, et al. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol. 2004;46(6):698-708.
47. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004, 15;64(6):1975-86.
48. Jerónimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res. 2004, 15;10(24):8472-8.
49. Bedford MT, van Helden PD. Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res. 1987, 15;47(20):5274-6.
50. Cho NY, Kim JH, Moon KC, Kang GH. Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch. 2009;454(1):17-23.
51. Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W,et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol. 2005, 20;23(27):6569-75.